News

The first expected targets for this research project would be the development of vaccines against prostate cancer and melanoma. This vaccine approach exploits the ability of bacteria to

The study (IR101-215), conducted at four sites in Italy, was designed to explore the potential utility of Remune and ongoing analysis will explore immunological information. The findings focused

Trexima, developed in collaboration with GlaxoSmithKline, is the proposed brand name for the single tablet that combines sumatriptan and naproxen. The drug demonstrated superiority over its individual components

Patient enrollment for the study began in Canada in December 2004, with the first patients being dosed in January 2005. BioMS anticipates that 30 trial sites will ultimately

The drug, phentermine hydrochloride, is approved for the short-term management of obesity. Lannett expects to commence marketing the product in June 2005. Arthur Bedrosian, president of Lannett, was

This is the first time that a modifiable risk factor for MS progression has been identified, providing a new strategy for patients hoping to control neurological damage from

Patients three to 17 years of age with polyarticular-course rheumatoid arthritis were recruited to the study. The children were given either methotrexate (brand names include Stada Pharmaceuticals’ Rheumatrex

Protein Design Labs (PDL)’s wholly-owned subsidiary, ESP Pharma, has acquired from Orphan Therapeutics exclusive marketing, sales and distribution rights for terlipressin in the US and Canada. Orphan Therapeutics

The study will examine the safety, tolerability and efficacy of AVR118 in patients with advanced cancer who are suffering from symptoms of progressive disease, including weight loss, fatigue